Galectin-3 levels in patients hospitalized for decompensated heart failure
dc.contributor.author | Rossel, Victor | |
dc.contributor.author | Diaz Toro, Felipe | |
dc.contributor.author | Verdejo, Hugo | |
dc.contributor.author | Concepcion, Roberto | |
dc.contributor.author | Sepulveda, Luis | |
dc.contributor.author | Castro, Pablo | |
dc.contributor.author | Luis Vukasovic, Jose | |
dc.contributor.author | Bernales, Angie | |
dc.contributor.author | Representacion Departmento Insufic | |
dc.date.accessioned | 2024-01-10T12:05:39Z | |
dc.date.available | 2024-01-10T12:05:39Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Galectin-3 (Gal-3) is a mediator of myocardial fibrosis involved in cardiac remodeling and a potential new prognosis marker in heart failure (HF). Aim: To measure Gal-3 at the moment of discharge in patients hospitalized for HF and its association with different variables. Material and Methods: Patients hospitalized for decompensated HF from four hospitals between August 2014 and March 2015, were included. Demographic, clinical and laboratory variables were recorded at the time of admission. At discharge, a blood sample was withdrawn to measure Gal-3 and brain natriuretic propeptide (Pro-BNP). Patients were separated in two groups, according to the level of Gal-3 (using a cutoff value of 17.8 ng/mL), comparing clinical and laboratory values between groups. Results: We included 52 patients with HF aged 70 17 years (42% females). Functional capacity was III-IV in 46% of patients and the ejection fraction was 34.9 13.4%. Pro-BNP values at discharge were 5,323 8,665 pg/mL. Gal-3 values were 23.8 16.6 ng/mL. Sixty percent of patients had values over 17.8 ng/mL. Those with elevated Gal-3 levels were older (75 16 and 62 15 years, respectively, p = 0.025) and were hypertensive in a higher proportion (90.5% and 57.1% respectively, p = 0.021). Conclusions: In patients hospitalized for HF, Gal-3 levels are higher in older and hypertensive subjects. | |
dc.fechaingreso.objetodigital | 2024-05-29 | |
dc.format.extent | 7 páginas | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.4067/s0034-98872017000600734 | |
dc.identifier.eissn | 0717-6163 | |
dc.identifier.issn | 0034-9887 | |
dc.identifier.pubmedid | MEDLINE:29171621 | |
dc.identifier.uri | https://doi.org/10.4067/s0034-98872017000600734 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/76046 | |
dc.identifier.wosid | WOS:000407985600007 | |
dc.information.autoruc | Medicina;Castro P;S/I;100212 | |
dc.information.autoruc | Medicina;Verdejo H;S/I;1001175 | |
dc.issue.numero | 6 | |
dc.language.iso | es | |
dc.nota.acceso | Contenido completo | |
dc.pagina.final | 740 | |
dc.pagina.inicio | 734 | |
dc.publisher | SOC MEDICA SANTIAGO | |
dc.revista | REVISTA MEDICA DE CHILE | |
dc.rights | acceso abierto | |
dc.subject | Biomarkers | |
dc.subject | Galectin-3 | |
dc.subject | Heart Failure | |
dc.subject | QUALITY-OF-LIFE | |
dc.subject | GENERAL-POPULATION | |
dc.subject | NATIONAL REGISTRY | |
dc.subject | PROGNOSTIC VALUE | |
dc.subject | MARKER | |
dc.subject | FIBROSIS | |
dc.subject | EPIDEMIOLOGY | |
dc.subject | PERSPECTIVE | |
dc.subject | DEPRESSION | |
dc.subject | BIOMARKERS | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Galectin-3 levels in patients hospitalized for decompensated heart failure | |
dc.type | artículo | |
dc.volumen | 145 | |
sipa.codpersvinculados | 100212 | |
sipa.codpersvinculados | 1001175 | |
sipa.index | WOS | |
sipa.index | Scopus | |
sipa.trazabilidad | Carga SIPA;09-01-2024 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Galectin-3 levels in patients hospitalized for decompensated heart failure.pdf
- Size:
- 296.95 KB
- Format:
- Adobe Portable Document Format
- Description: